Familial Alzheimer’s Disease Mutations in PSEN1 Lead to Premature Human Stem Cell Neurogenesis

Graphical Abstract

Highlights

- In neurogenesis, PSEN1 expression is enriched in progenitors, as it is for APP in neurons
- Inhibiting β-secretase has little effect on neurogenesis, contrary to γ-secretase
- Familial Alzheimer’s disease mutations in PSEN1 cause premature neurogenesis
- Trend toward fewer newborn neurons in familial AD postmortem hippocampi

Authors

Charles Arber, Christopher Lovejoy, Lachlan Harris, ..., Nick C. Fox, Tammaryn Lashley, Selina Wray

Correspondence

c.arber@ucl.ac.uk (C.A.), selina.wray@ucl.ac.uk (S.W.)

In Brief

Arber et al. employ human iPSC neurogenesis to model adult hippocampal neurogenesis, investigating familial Alzheimer’s disease (fAD) mutations. In contrast to APP, PSEN1 and γ-secretase components are enriched in neural progenitors and mutations drive premature neurogenesis. Postmortem fAD hippocampi show corresponding trends toward altered neurogenesis.
Familial Alzheimer’s Disease Mutations in PSEN1 Lead to Premature Human Stem Cell Neurogenesis

Charles Arber,1,7,* Christopher Lovejoy,1 Lachlan Harris,2 Nanet Willumsen,1,3 Argyro Alatza,1 Jackie M. Casey,1 Georgie Lines,1 Caoimhe Kerins,1 Anika K. Mueller,1 Henrik Zetterberg,1,4,5,6 John Hardy,1,6 Natalie S. Ryan,1,6 Nick C. Fox,1,6 Tammaryn Lashley,1,3 and Selina Wray1,*

1Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
2Neural Stem Cell Biology Laboratory, The Francis Crick Institute, London, UK
3Queen Square Brain Bank for Neurological Disorders, Department of Clinical and Movement Neuroscience, UCL Queen Square Institute of Neurology, London, UK
4Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Malmö, Sweden
5Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Malmö, Sweden
6UK Dementia Research Institute at UCL, London, UK
7Lead Contact
*Correspondence: c.arber@ucl.ac.uk (C.A.), selina.wray@ucl.ac.uk (S.W.)
https://doi.org/10.1016/j.celrep.2020.108615

SUMMARY

Mutations in presenilin 1 (PSEN1) or presenilin 2 (PSEN2), the catalytic subunit of γ-secretase, cause familial Alzheimer’s disease (fAD). We hypothesized that mutations in PSEN1 reduce Notch signaling and alter neurogenesis. Expression data from developmental and adult neurogenesis show relative enrichment of Notch and γ-secretase expression in stem cells, whereas expression of APP and β-secretase is enriched in neurons. We observe premature neurogenesis in fAD iPSCs harboring PSEN1 mutations using two orthogonal systems: cortical differentiation in 2D and cerebral organoid generation in 3D. This is partly driven by reduced Notch signaling. We extend these studies to adult hippocampal neurogenesis in mutation-confirmed postmortem tissue. fAD cases show mutation-specific effects and a trend toward reduced abundance of newborn neurons, supporting a premature aging phenotype. Altogether, these results support altered neurogenesis as a result of fAD mutations and suggest that neural stem cell biology is affected in aging and disease.

INTRODUCTION

Mutations in amyloid precursor protein (APP) and presenilin 1 and 2 (PSEN1/2) cause familial Alzheimer’s disease (fAD) (Goate et al., 1991; Levy-Lahad et al., 1995; Sherrington et al., 1995). PSEN1/2 and APP exist on the same molecular pathway: PSEN1 is the catalytic subunit of γ-secretase, a transmembrane enzyme that cleaves APP to generate β-amyloid (Aβ). The amyloid cascade hypothesis theorizes that fAD mutations increase either the amount of Aβ produced or the proportion of amyloidogenic Aβ moieties, leading to aggregation and predisposing neurodegeneration (Selkoe and Hardy, 2016). PSEN1 mutations achieve this via destabilization of the enzyme-substrate interaction, increasing the relative levels of longer, more aggregation-prone forms of Aβ (Chávez-Gutiérrez et al., 2012; Szaruga et al., 2017).

In addition to APP, γ-secretase cleaves a host of other type I transmembrane substrates (reviewed in Haapasalo and Kovacs, 2011), altered cleavage of which could potentially contribute to the clinical heterogeneity seen among PSEN1 mutations (Ryan et al., 2016). One example is the cell-signaling factor Notch. After binding of the Notch receptor to Jagged and DLL ligands on neighboring cells, α- and γ-secretases cleave the Notch protein to release a transcriptionally active intracellular domain (Notch intracellular domain [NICD]). A subset of fAD mutations has been shown to reduce the cleavage of Notch by γ-secretase (Chávez-Gutiérrez et al., 2012; Song et al., 1999), thereby decreasing Notch signaling.

Notch signaling is required for several cell-contact-dependent processes, an example of which is the maintenance of stemness in the stem cell niche. As such, human stem cell neurogenesis in vitro relies on Notch signaling, and inhibition of Notch cleavage through γ-secretase inhibitors leads to rapid terminal differentiation of neural precursors (Borghese et al., 2010; Main et al., 2013; Woo et al., 2009). In addition, active Notch signaling is required for progressive rounds of differentiation from cortical progenitors, orchestrating temporal patterning toward different cortical-layer fates (Edri et al., 2015). Continued Notch signaling may be important for the persistence of stemness and the establishment of adult neurogenic cells (Edri et al., 2015), and there is evidence that tissue-resident neural stem cells (NSCs) maintain developmental neurogenesis programs in the adult brain (Berg et al., 2019).

Adult neurogenesis is the process whereby new neurons are generated from NSCs in the subventricular zone (SVZ) of the cortex and the dentate gyrus of the hippocampus (Altman...
It is agreed that adult neurogenesis is a rare event that drops sharply after birth, yet there is some contention over its persistence into old age (Boldrini et al., 2018; Sorrells et al., 2018). Decreased neurogenesis correlates with cognitive decline in Alzheimer’s disease (AD) patients when compared with non-demented individuals with Alzheimer’s-like pathology (Briley et al., 2016). Indeed, both psen1 knockout mice (Bonds et al., 2015; Handler et al., 2000; Saura et al., 2004) and animals harboring fAD mutations (Hamilton et al., 2010; Haughey et al., 2002; Wen et al., 2002, 2004) show disrupted neurogenesis and reduced learning and memory. Enhanced neurogenesis has also been described in psen1/2 double-knockout mice (Chen et al., 2008). In addition, rodent models of human APOE4 (Adeosun et al., 2014; Li et al., 2009) or apoE deficiency display enhanced neurogenesis (Li et al., 2009; Yang et al., 2011). However, effects may be nuanced, with increased neurogenesis in young mice and a subsequent reduction in neurogenesis in older apoE knockout mice (Tensauitli et al., 2018; Yang et al., 2011) and APOE4 mice (Tensauitli et al., 2018). In agreement, studies using human postmortem brain tissue showed that neurogenesis was reduced in AD patients (Moreno-Jiménez et al., 2019) and in early-onset AD patients (Crews et al., 2010) and was correlated with cognitive performance (Tobin et al., 2019). However, there is evidence to contradict these findings (Bookhoorn et al., 2006; Jin et al., 2004). Altogether, these data suggest that fAD mutations that perturb Notch signaling could negatively affect appropriate γ-secretase-dependent neurogenesis.

PSEN1 has been shown to be critical for appropriate embryonic neurogenesis (Handler et al., 2000), which led us to investigate the effect of mutations in APP and PSN1 on stem cell neurogenesis using both induced pluripotent stem cell (iPSC) differentiation models and postmortem brain tissue from fAD mutation carriers. We hypothesized that mutations in PSN1 that reduce γ-secretase activity would lead to premature terminal differentiation via reduced Notch signaling, an effect not predicted for APP mutant cells.

RESULTS

Spatiotemporal Restriction of Notch, γ-Secretase, and APP in Human Development

To compare γ-secretase-, Notch-, and APP-associated gene expression during human development, data were leveraged from the BrainSpan reference atlas (Miller et al., 2014). Cortical-layer-specific gene expression relative to the overall mean was compared using expression data from fetal tissue 15 to 21 weeks after conception (Figure 1A).

As expected, Notch ligands and receptors are enriched in the ventricular zone and the SVZ of the developing cortex, representing progenitor cell populations. In general, γ-secretase subunits displayed similar enrichment in the progenitor layers with alternate subunits displaying differential distributions; for example, PSEN1 and APH1B displayed enrichment in proliferative cells, whereas PSEN2 and APH1A showed enrichment in terminally differentiated neurons. In addition, z-secretase expression was enriched in the progenitor populations, whereas β-secretase and APP expression was highest in postmitotic neuronal layers. In addition, APP family members showed differing expression patterns, with APLP2 enrichment in progenitors in contrast to the neurally expressed APP and APLP1.

To validate these expression data, we investigated protein distribution in developing human cerebral organoids via immunofluorescence (Figure 1B; Figure S1). Cells follow intrinsic differentiation cues to organize into a proliferative zone, akin to the SVZ of the developing brain, and a neuronal cortical plate-like region as neurons mature and migrate from the SVZ (Renner et al., 2017). Active Notch signaling was highest in neurogenic regions, shown via detection of the cleaved NICD. In contrast, APP was restricted to postmitotic neuronal regions. PSN1 displayed a more ubiquitous expression pattern.

These data support a spatiotemporal separation of the γ-secretase substrates APP and Notch in different developmental states. β- and α-secretase expression also show distinction, a finding supported by data showing that APP fragments generated by α-secretase (Aβ16) appear early in iPSC differentiation compared with the later β-secretase-dependent fragments (Aβ40 and Aβ42) (Bergström et al., 2016). In addition, the data support distinction of alternate γ-secretase subunits between cell identities, building on reports that PSN1 and PSEN2 exhibit differences in subcellular compartmentalization (Sannerud et al., 2016).

γ-Secretase and β-Secretase Inhibition Have Distinct Effects on Neurogenesis

Given the spatiotemporal distinction between γ- and β-secretase subunit expression, we next investigated the functional impact of inhibiting both enzymes on stem cell neurogenesis.

As previously described in the literature, DAPT-mediated γ-secretase inhibition of neural precursors led to a dramatic exit from the cell cycle concurrent with terminal differentiation (Figure 2; Figure S2) (Borgese et al., 2010; Main et al., 2013; Woo et al., 2009). This is demonstrated via reduced total cell numbers, a lower population of cells expressing the proliferative marker Ki67, and increased expression of the neuronal marker TUJ1. In contrast, treatment with the β-secretase inhibitor LY2886721 led to no significant effect on the balance between proliferation and neurogenesis. This finding supports the distinct roles of β- and γ-secretases on neural development.

IAD Mutations Cause Premature Differentiation In Vitro

Next we investigated the consequence of mutations in PSN1 and APP on neurogenesis using a panel of 5 control iPSC lines and 7 lines harboring different fAD mutations at day 27 of cortical differentiation, a time point of neuronal commitment (Shi et al., 2012). The panel consisted of two independent lines with the APP V717I mutation and five separate PSN1 mutations: intron 4 deletion (int4del), Y115H, M139V, M146I, and R278I (see STAR Methods) (previously described in Arber et al., 2020).

Morphologically, the two lines harboring the PSN1 mutations int4del and Y115H displayed a striking premature differentiation phenotype, shown via earlier formation of neural projections relative to other lines (Figure 3A; Figure S2). We have previously shown that these mutations, which affect the extracellular substrate docking domain of PSN1 (Somavarapu and Kepp, 2016; Takagi-Nidome et al., 2015), potentially...
reduce γ-secretase activity to a larger degree than the other mutations tested (Arber et al., 2020). Therefore, subgroup analysis of these lines was performed (pink histograms). High-content imaging, qPCR expression data, and western blot analysis supported a small but consistent premature differentiation phenotype in all lines harboring PSEN1 mutations (int4del, Y115H, M139V, M146I, and R278I) (Figures 3A–3E). High-content imaging was used to assess levels of the postmitotic neuronal marker TUJ1 and a marker of proliferating precursor cells, Ki67 (Figures 3A and 3B). When compared with pooled control data, the PSEN1 int4del and Y115H lines showed significantly reduced numbers of proliferative progenitor cells.
Furthermore, when all lines bearing PSEN1 mutations were pooled and compared with pooled control data, there was a trend toward an increased proportion of postmitotic neurons. Western blotting revealed a reduction in levels of cleaved, active Notch in lines bearing PSEN1 mutations (Figures 3C and 3D), representing reduced g-secretase-dependent Notch signaling, a reduction that was especially striking in the PSEN1 int4del and Y115H lines (p = 0.0047). This was in addition to a trend toward decreased levels of neural progenitor marker PAX6 and increased levels of TUJ1 (p = 0.0028) (Figures 3C and 3D). qPCR analysis was then used to assess the expression levels of the brain-specific Notch signaling readout gene FABP7 (alias BLBP) (Anthony et al., 2005), which displayed significantly reduced (p = 0.0083) expression in lines harboring PSEN1 mutations compared with controls (Figure 3E). This was accompanied by significantly increased (p = 0.0310) expression of the neuronal-specific TUBB3 gene (for which TUJ1 is the gene product). Progenitors harboring the APP V717I mutation displayed differentiation comparable to that of controls. FABP7 expression was 20–40 times higher than that of the HES family genes HES1, HES5, and HEY1, alternate Notch readout genes that showed largely a similar expression pattern among genotypes.

The increased expression of neuronal markers and reduced abundance of progenitor cells in cultures harboring PSEN1 mutations can be depicted by the ratio of PAX6 to TUJ1 protein abundance, made possible because of similar molecular weights (Figure 3C). This finding supports premature neuronal commitment. A depletion of NSC marker expression in PSEN1 mutant neuronal cultures compared with isogenic control cultures can be independently verified in published expression data (Figure 3F) (Kwart et al., 2019).

To validate the observed early terminal differentiation, we employed an orthogonal iPSC neurogenesis model, namely, 3D cerebral organoid differentiation. The relative contribution of progenitor cells versus committed neurons was assessed by immunocytochemistry (Figures 4A and 4B). This approach supported an increased neuronal contribution in PSEN1 mutant lines relative to neural progenitors (p = 0.0266) (Figure 4C). In contrast, APP V717I lines displayed significantly larger total neurogenic regions (p = 0.0133), albeit with relative precursor and neuronal contributions similar to those of controls (Figure 4D).

These data support a premature differentiation phenotype in iPSC lines harboring mutations in PSEN1, and this effect can partly be explained via reduced Notch signaling. Analysis of two iPSC lines harboring the APP V717I mutation suggest premature differentiation may be specific to PSEN1 mutant lines. The APOE genotype has been reported to affect neurogenesis (Adeosun et al., 2014; Li et al., 2009), but regrouping our data based on the APOE genotype of each line did not explain this.
Figure 3. Mutations in PSEN1 Reduce Notch Signaling and Lead to Premature Terminal Differentiation

(A) Representative images of day 27 iPSC-derived neural progenitors labeled for dividing cells (Ki67) and postmitotic neurons (TUJ1).

(B) High-content analysis and quantification of the relative proportion of proliferative (Ki67 positive) and neuronal (TUJ1 positive) cells.

(C and D) Representative western blot and quantification for the cleaved, active Notch intracellular domain (NICD), PAX6 neural progenitor marker, and TUJ1 neuronal marker. Note, due to variability in Ctrl1, PAX6 data were normalized to Ctrl2. Due to similar molecular weights, the ratio of PAX6 to TUJ1 intensity represents a measure of terminal differentiation. na, not available.

(E) qPCR analysis of the expression of the Notch readout gene FABP7 (alias BLBP) and TUBB3 (neuronal tubulin).

(legend continued on next page)
phenotype, suggesting that PSEN1 mutations are indeed driving this effect (Figure S3).

**Expression of Notch-, App-, and β/γ-Secretase-Associated Genes in Mouse Adult Hippocampal Neurogenesis**

Previously reported single-cell RNA sequencing (scRNA-seq) data delineating neurogenic lineages from mouse hippocampi (Hochgerner et al., 2018) was reanalyzed to explore the expression of Notch, App, and γ-secretase components (Figure 5). Relative expression enrichment was compared among NSCs, intermediate neural progenitor cells (IPCs), and hippocampal granule neurons (Figures 5B–5G).

The Notch signaling readout gene (Fabp7) was enriched in NSC populations compared with neurons (Figure 5B). γ-secretase components Psen1 and Psen2 were detected but below the threshold for differential gene expression analysis; however, the obligate γ-secretase subunit Psenen showed significant enrichment in NSCs (Figures 5C–5E). In contrast, App and Bace1 expression displayed significant enrichment in neuronal cells compared with NSCs (Figures 5F and 5G).

These data also reinforce the role for γ-secretase and Notch signaling in NSCs in vivo.

**Neurogenesis in Postmortem fAD Tissue**

We postulated that mutations in PSEN1, but not APP, might also affect adult hippocampal neurogenesis in the dentate gyri of fAD patients. To examine the impact of fAD mutations on NSCs in vivo, hippocampi from mutation-confirmed fAD postmortem brains were compared with non-age-matched control brains (see STAR Methods). Manual counting analysis was conducted by three independent and blinded scorers. NSCs were quantified using the cytoskeletal marker NESTIN, and newly committed neurons were quantified via TUJ1-positive neurites crossing the granule cell layer of the dentate gyrus. TUJ1 is shown to be highly enriched in newly formed neurons, and expression reduces with cellular maturity (von Bohlen Und Halbach, 2007; Gómez et al., 2017). Thus, this measure provided a proxy for neurogenesis over a large temporal window, and cytoskeletal markers potentially may be less prone to the effects of postmortem delay that is seen for extracellular markers such as DCX (Boekhoorn et al., 2006) and PSA-NCAM.

Analyses showed that TUJ1-positive projections were detectable in all hippocampi (Figures 6A and 6B). There were no significant differences in the abundance of TUJ1-positive cells among genotype groups (Figure S4), despite clear differences among individuals. One control individual displayed few TUJ1-positive fibers, and this data point may skew otherwise significant differences, namely, reduced neurogenesis in fAD cases. Despite the lack of significance, interesting mutation-specific comparisons exist, including a significant increase in the number of TUJ1-positive neurites in the PSEN1 M139V case compared with the other PSEN1 mutations (comparisons made using multiple fields of view from individual cases). The PSEN1 M139V mutation has been shown to have little effect on Notch endoproteolytic cleavage (Chávez-Gutiérrez et al., 2012). The in vitro data in this study are consistent with a less pronounced phenotype in the PSEN1 M139V iPSC line compared with other fAD mutations, e.g., NICD western blotting (Figures 3C and 3D).

Next, we reasoned that premature differentiation observed in vitro may correspond to a depletion of the stem cell pool in vivo, similar to the effects of aging (Encinas et al., 2011). Quantification of NESTIN-positive NSCs in the granule cell layer highlighted consistent levels of NESTIN staining across all genotypes, arguing against an effect on the stem cell pool in fAD (Figures 6C and 6D; Figure S4).

When neurogenesis (TUJ1-positive neurite density) was correlated with age at death in control cases (Figure 6E), a trend toward reduced neurogenesis with advancing age was observed, supporting an overall reduction in neurogenesis with increasing age. The data highlight the younger age at death of the fAD cases but also a reduced age effect in the PSEN1 mutation carriers, shown by the gradient of the regression. This suggests that the effect of PSEN1 mutations on neurogenesis is dominant over age. In addition, we observed a trend for increased neurogenesis in individuals with longer disease duration (Figure 6F).

It is crucial to acknowledge the rarity of fAD postmortem tissue availability and the low number of brains analyzed in this study. However, interesting trends emerge that require further investigation. Neurogenesis has been shown to decline with age (Ben Abdallah et al., 2010; Leuner et al., 2007; Spalding et al., 2013). The lack of significant difference between fAD hippocampi (average age at death of 56 years; see STAR Methods) and control hippocampi (average age at death of 88 years) supports a dominant effect of the mutations on neurogenesis, in addition to the effect of aging.

**DISCUSSION**

This study demonstrates that the process of neurogenesis is affected by mutations that cause fAD. Mutations in PSEN1 lead to a small yet significant premature differentiation phenotype, whereas the V717I mutation in APP may increase total

(F) RNA sequencing (RNA-seq) expression data from Kwart et al. (2019), demonstrating expression of neuronal stem cell (NSC) markers (PAX6, NES, and SOX2), Notch signaling readout genes (FABP7, HES1, and HES5), and adult NSC markers (HOPX, LGALS1, and ANXA2) (Berg et al., 2019; Edri et al., 2015) in 80 days in vitro (DIV) iPSC-derived neurons from wild type (WT) compared with isogenic PSEN1 or APP mutant lines. Adjusted p values are represented within the histogram.

Blue, control; purple, APP mutant cells; pink, mutations in the PSEN1 extracellular loop; green, mutations in PSEN1 transmembrane and intracellular domains. The number of independent neural inductions is shown within the histograms. Data from different iPSC clones are depicted by gray data points (APP V717I, PSEN1 int4del, and PSEN1 R278I). *p < 0.05, **p < 0.01, ***p < 0.001 via ANOVA with post hoc Tukey’s analysis (normal distribution tested via the Shapiro-Wilk test), as indicated in Table S1. Scale bar represents 50 μm. Error bars represent standard error of the mean.
neurogenesis. The \textit{PSEN1} mutations int4del and Y115H in the substrate docking domain of the enzyme (Somavarapu and Kepp, 2016; Takagi-Niidome et al., 2015) have the strongest phenotype.

These data support previous observations in the literature. The \textit{PSEN1} S169del and A246E mutations have been shown to lead to premature iPSC neurogenesis (Yang et al., 2017). The authors propose that this phenotype could be driven by changes to Notch signaling but also suggest defects in the Wnt signaling pathway. Similar findings of premature differentiation have been described for sporadic AD-patient-derived iPSC differentiation, whereby the authors describe changes in the REST-mediated transcriptional programs causing early differentiation and hyper-excitability in young neurons (Meyer et al., 2019).

Our data support the finding that dominantly inherited fAD mutations in \textit{PSEN1} are sufficient to drive premature neural commitment. Sporadic AD iPSCs and \textit{APOE} ε4-carrying cells can independently display premature neuronal commitment (Meyer et al., 2019), which suggests that this complex phenotype is likely to rely on multiple factors. That stated, the \textit{APOE} genotype was not able to explain the presented data, because grouping the lines by \textit{APOE} status did not highlight significant effects on neurogenesis (Figure S3).

Our data stratify fAD mutations as having different effects on neurogenesis. Mutations in the substrate docking domain of \textit{PSEN1} have the strongest premature neurogenesis phenotype compared with other \textit{PSEN1} mutation lines. What is more, \textit{PSEN1} and \textit{APP} mutations affect neurogenesis distinctly. These differences are presumed to relate to mutation effects on enzyme versus substrate, whereby \textit{PSEN1} mutations alter \(\gamma\)-secretase-substrate interactions, including both Notch and APP (Szaruga et al., 2017), whereas \textit{APP} mutations alter \(\gamma\)-secretase-APP interactions without affecting Notch. However, extracellular fragments of APP have been suggested to function as mitogenic signals in the adult neurogenic niche (Caille´ et al., 2004), and conversely, the APP intracellular domain has been suggested to be part of a transcriptional complex that negatively regulates neurogenesis (Ma et al., 2008); therefore, \textit{APP} mutations may affect neurogenesis through complex mechanisms. The enlarged neurogenic contribution of our \textit{APP} mutation carrier organoids supports these studies.

We hypothesize that the observed neurogenesis effects in \textit{PSEN1} mutants are mediated via changes to Notch signaling. Notch is processed in a manner similar to APP, whereby \(\gamma\)-secretase is responsible for the rate-limiting cleavage step, and both APP and Notch physically interact (Oh et al., 2005). Appropriate Notch signaling is required for most stem cell populations, and the Notch readout gene \textit{FABP7} investigated in the present study can be used as a stem cell marker in the adult brain (Varela-Nallar et al., 2010). The importance for Notch-\(\gamma\)-secretase interactions is...
highlighted by the halting of γ-secretase inhibitor trials due to off-target effects on Notch signaling (Doody et al., 2013). In support of the role of aberrant Notch signaling in AD, Notch proteins have been shown to be a component of amyloid plaques in postmortem tissue (Brai et al., 2016) and the Notch ligand Jagged is reduced in AD (Marathe et al., 2017). Further work is required to disentangle cell-autonomous versus non-cell-autonomous pathomechanisms of fAD mutations on neurogenesis. The current work suggests a cell-autonomous reduction in Notch signaling as a major driver, with our recent work using an isogenic PSEN1 int4del allelic series suggesting that this is not via a simple loss-of-function mechanism (Arber et al., 2019). However, previous work has implicated non-cell-autonomous functions of APP cleavage (Caille et al., 2004), and the roles of secreted APP, distinct Aβ moieties, and Notch ligands should be further explored with respect to neurogenesis and fAD. With this in mind, care should be taken when comparing psen1 knockout mice with fAD models; Meyer et al. (2019) did not witness altered Notch signaling in their iPSC models of sporadic Alzheimer’s disease.

It is compelling that Notch pathway gene expression and γ-secretase components are spatiotemporally enriched in neural precursors. The enrichment for APP and β-secretases in postmitotic neurons reinforces the lack of effect of APP V717I on Notch signaling in neural progenitors. The different roles of β- and γ-secretases are supported by the distinct responses of control neuronal precursors to β-secretase and γ-secretase inhibition. Importantly, bace1 knockout mice show increased proliferation but decreased neurogenesis in the adult brain (Chatila et al., 2018), whereas psen1 knockout mice show increased neuronal differentiation (Handler et al., 2000). As single-cell expression datasets encompassing human aging and fAD hippocampi become available, it will be important to validate these findings.

It is intriguing that we see deficits in embryonic neuronal development, modeled by iPSC differentiation, whereas fAD clinical symptoms manifest from the fourth decade of life. Despite this disparity, evidence exists to suggest that fAD mutation carriers may have altered brain development. MRI scans have shown increased brain volume in children harboring PSEN1 E280A mutations (Quiroz et al., 2015) and structural changes have been described in children who are APOE4 carriers (Dean et al., 2014). However, these changes could reflect neuroinflammatory responses to early disease processes, in contrast to developmental effects. Despite these changes, our fAD iPSCs generate the appropriate proportions of cortical-layer markers after 100 days of differentiation (Arber et al., 2020), suggesting that neurogenic timing is altered, rather than developmental specification.

Studies suggest that hippocampal neurogenesis is reduced in the brains of patients with sporadic AD and mild cognitive...
impairment compared with age-matched controls (Moreno-Jiménez et al., 2019; Tobin et al., 2019). However, this remains controversial (Boldrini et al., 2018; Kempermann et al., 2018; Paredes et al., 2018; Sorrells et al., 2018; Tartt et al., 2018), and previous studies comparing AD postmortem brains have described opposing effects of the disease on neurogenesis (Boekhoorn et al., 2006; Crews et al., 2010; Jin et al., 2004). Our data describe neurogenesis in genetically confirmed fAD. The data do not support significant changes in adult hippocampal neurogenesis in fAD, yet they suggest some trends toward (1) reduced neurogenesis in fAD, supporting previous work on early-onset AD (Crews et al., 2010); (2) a disease-associated reduction in neurogenesis, despite younger NSC niches; and (3) mutation-specific effects, such as the reduced impact of the PSEN1 M139V mutation on Notch cleavage compared with other mutations. These fAD cases show similar Braak staging. It will be interesting to further explore the relative contribution of tau and Aβ pathologies versus mutation-specific Notch signaling defects in neurogenesis dysfunction.

In vivo analysis of neurogenesis in fAD tissue is limited by the paucity of available tissue because of the rarity of the disease. In addition, we are unable to control for neurodegeneration, meaning that we cannot discount that cell death may have a more general impact on adult hippocampal neurogenesis. Indeed, neurogenesis and neuronal cell death have been shown to be interdependent and closely related to cognitive decline (Choi et al., 2018).
Further experiments are required to test the hypothesis that fAD leads to a depletion of the stem cell pool with advancing age and contrast with the vulnerability of newborn neurons in relation to neurodegenerative processes. Defects in early-adult neurogenesis appear to be central for neuron vulnerability associated with later-stage AD in mouse models (Choi et al., 2018). This is reinforced as mice with a conditional Psen1 knockout on a Psen2 knockout background show stage-dependent effects on neurogenesis, with early enhancement of neurogenesis followed by a decline at late stages of disease with concomitant neuroblast vulnerability (Chen et al., 2008; Unger et al., 2016). The RESTIN staining presented here does not support an NSC depletion hypothesis but is in line with previous reports of unchanged RESTIN staining in AD model mice (Unger et al., 2016). Further analysis with alternative NSC- and Notch-associated immunohistochemistry is required to explore this question.

In summary, we have described a premature differentiation phenotype in human stem cell neurogenesis in vitro resulting from fAD mutations in PSEN1, with relevance to in vivo neurogenesis. PSEN1 and APP mutations have distinct effects on neurogenesis, whereby our data support Notch signaling deficits that depend on PSEN1 mutations, whereas overall neurogenesis is enhanced in organoids bearing APP mutations. These findings suggest that fAD mutations alter the timing of neurogenesis during development and throughout life, accelerating aging and predisposing neurodegeneration. These findings and genetic distinctions should be considered when future clinical studies targeting β- and γ-secretase are designed and analyzed.

**STAR METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - Lead Contact
  - Materials Availability
  - Data and Code Availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Details of stem cell lines employed
  - Case information for post-mortem brain tissue
- **METHOD DETAILS**
  - Cell culture
  - Aβ42 ELISAs
  - Immunocytochemistry
  - Immunohistochemistry
  - qPCR
  - Western blotting
  - BrainSpan data
  - Analysis of single cell RNA-seq data
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
  - Statistics

**SUPPLEMENTAL INFORMATION**

Supplemental Information can be found online at https://doi.org/10.1016/j.celrep.2020.108615.

**ACKNOWLEDGMENTS**

C.A. is supported by a junior fellowship from the Alzheimer’s Society (AS-JF-18-008). S.W. and T.L. are supported by Alzheimer’s Research UK senior fellowships (ARUK-SRF2016B-2 and ARUK-SRF2015-2, respectively). N.S.R. is funded by a University of London Chadburn Academic Clinical Lectureship in Medicine. N.C.F. acknowledges the support of the UK Dementia Research Institute. The Queen Square Brain Bank is supported by the Reta Lila Weston Institute of Neurological Studies and UCL Queen Square Institute of Neurology. This work was supported by UK Medical Research funding (MR/M02492X/1 and MC_U122668) and the National Institute for Health Research University College London Hospitals Biomedical Research Centre.

**AUTHOR CONTRIBUTIONS**

Investigation, C.A., C.L., L.H., N.W., A.A., J.M.C., G.L., O.K., and A.K.M.; Writing – Original Draft, C.A. and S.W.; Writing – Reviewing & Editing, all authors; Resources, N.S.R. and T.L.; Supervision & Funding Acquisition, H.Z., J.H., N.C.F., T.L., and S.W.

**DECLARATION OF INTERESTS**

H.Z. has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteo Therapeutics, and CogRx; has given lectures in symposia sponsored by Fujirebio, Alzecure, and Biogen; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. The other authors have no conflicts of interest to declare.

Received: April 28, 2020
Revised: September 7, 2020
Accepted: December 16, 2020
Published: January 12, 2021

**REFERENCES**

Adeosun, S.O., Hou, X., Zheng, B., Stockmeier, C., Ou, X., Paul, I., Mosley, T., Weisgraber, K., and Wang, J.M. (2014). Cognitive deficits and disruption of neurogenesis in a mouse model of apolipoprotein E4 domain interaction. J. Biol. Chem. 289, 2946–2959.

Altman, J., and Das, G.D. (1965). Autoradiographic and histological evidence of postnatal hippocampal neurogenesis in rats. J. Comp. Neurol. 124, 319–335.

Anthony, T.E., Mason, H.A., Gridley, T., Fishell, G., and Heintz, N. (2005). Brain lipid-binding protein is a direct target of Notch signaling in radial glial cells. J. Biol. Chem. 280, 2946–2959.

Arber, C., Toombs, J., Lovejoy, C., Ryan, N.S., Paterson, R.W., Willumsen, N., Gkanatsiou, E., Portelius, E., Biennow, K., Heslegrave, A., et al. (2020). Familial Alzheimer’s disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta. Mol. Psychiatry 25, 2919–2931.

Arber, C., Villegas-Llerena, C., Toombs, J., Pocock, J.M., Ryan, N.S., Fox, N.C., Zetterberg, H., Hardy, J., and Wray, S. (2019). Amyloid precursor protein processing in human neurons with an allelic series of the PSEN1 intron 4 deletion mutation and total presenilin-1 knockout. Brain Commun. 1, fcz024.

Ben Abdallah, N.M.B., Slomianka, L., Vyssotski, A.L., and Lipp, H.P. (2010). Early age-related changes in adult hippocampal neurogenesis in C57 mice. Neurobiol. Aging 31, 151–161.

Berg, D.A., Su, Y., Jimenez-Cyrus, D., Patel, A., Huang, N., Morizet, D., Lee, S., Shah, R., Ringeling, F.R., Jain, R., et al. (2019). A Common Embryonic Origin of Stem Cells Drives Developmental and Adult Neurogenesis. Cell 177, 654–668.e15.

Bergström, P., Agholme, L., Nazir, F.H., Satir, T.M., Toombs, J., Wellington, H., Strandberg, J., Bontell, T.O., Kvartserg, H., Holmström, M., et al. (2016). Amyloid precursor protein expression and processing are differentially regulated during cortical neuron differentiation. Sci. Rep. 6, 29200.
Boekhoom, K., Joels, M., and Lucassen, P.J. (2006). Increased proliferation reflects glial and vascular-associated changes, but not neurogenesis in the presenile Alzheimer hippocampus. Neurobiol. Dis. 24, 1–14.

Boldrini, M., Fulmore, C.A., Tartt, A.N., Simeon, L.R., Pavlova, I., Popsoska, V., Rosokija, G.B., Stankov, A., Arango, V., Dwork, A.J., et al. (2018). Human Hippocampal Neurogenesis Persists throughout Aging. Cell Stem Cell 22, 589–599.e5.

Bonds, J.A., Kuttner-Hirschler, Y., Bartolotti, N., Tobin, M.K., Pizzi, M., Marr, R., and Lazarov, O. (2015). Presenilin-1 dependent neurogenesis regulates hippocampal learning and memory. PLoS ONE 10, e0131266.

Borghese, L., Dolezalova, D., Optiz, T., Haupt, S., Lempiau, A., Steinfarz, B., Koch, P., Edenhofer, F., Hampi, A., and Brustle, O. (2010). Inhibition of notch signaling in human embryonic stem cell-derived neural stem cells delays G1/S phase transition and accelerates neural differentiation in vitro and in vivo. Stem Cells 28, 955–964.

Brau, E., Alina Raio, N., and Alberi, L. (2016). Notch1 hallmarks fibroblastic positions in sporadic Alzheimer’s disease. Acta Neuropathol. Commun. 4, 64.

Briley, D., Ginardi, V., Wolfer, R., Renck, A., Zolochevska, A., Taglialatela, G., Koch, P., Edenhofer, F., Hampi, A., and Brustle, O. (2010). Inhibition of notch signaling in human embryonic stem cell-derived neural stem cells delays G1/S phase transition and accelerates neuronal differentiation in vitro and in vivo. Stem Cells 28, 955–964.

Briley, D., Ginardi, V., Wolfer, R., Renck, A., Zolochevska, A., Taglialatela, G., Koch, P., Edenhofer, F., Hampi, A., and Brustle, O. (2010). Inhibition of notch signaling in human embryonic stem cell-derived neural stem cells delays G1/S phase transition and accelerates neuronal differentiation in vitro and in vivo. Stem Cells 28, 955–964.

Brau, E., Alina Raio, N., and Alberi, L. (2016). Notch1 hallmarks fibroblastic positions in sporadic Alzheimer’s disease. Acta Neuropathol. Commun. 4, 64.

Briley, D., Ginardi, V., Wolfer, R., Renck, A., Zolochevska, A., Taglialatela, G., Koch, P., Edenhofer, F., Hampi, A., and Brustle, O. (2010). Inhibition of notch signaling in human embryonic stem cell-derived neural stem cells delays G1/S phase transition and accelerates neuronal differentiation in vitro and in vivo. Stem Cells 28, 955–964.

Brau, E., Alina Raio, N., and Alberi, L. (2016). Notch1 hallmarks fibroblastic positions in sporadic Alzheimer’s disease. Acta Neuropathol. Commun. 4, 64.

Briley, D., Ginardi, V., Wolfer, R., Renck, A., Zolochevska, A., Taglialatela, G., Koch, P., Edenhofer, F., Hampi, A., and Brustle, O. (2010). Inhibition of notch signaling in human embryonic stem cell-derived neural stem cells delays G1/S phase transition and accelerates neuronal differentiation in vitro and in vivo. Stem Cells 28, 955–964.

Brau, E., Alina Raio, N., and Alberi, L. (2016). Notch1 hallmarks fibroblastic positions in sporadic Alzheimer’s disease. Acta Neuropathol. Commun. 4, 64.

Briley, D., Ginardi, V., Wolfer, R., Renck, A., Zolochevska, A., Taglialatela, G., Koch, P., Edenhofer, F., Hampi, A., and Brustle, O. (2010). Inhibition of notch signaling in human embryonic stem cell-derived neural stem cells delays G1/S phase transition and accelerates neuronal differentiation in vitro and in vivo. Stem Cells 28, 955–964.

Brau, E., Alina Raio, N., and Alberi, L. (2016). Notch1 hallmarks fibroblastic positions in sporadic Alzheimer’s disease. Acta Neuropathol. Commun. 4, 64.

Briley, D., Ginardi, V., Wolfer, R., Renck, A., Zolochevska, A., Taglialatela, G., Koch, P., Edenhofer, F., Hampi, A., and Brustle, O. (2010). Inhibition of notch signaling in human embryonic stem cell-derived neural stem cells delays G1/S phase transition and accelerates neuronal differentiation in vitro and in vivo. Stem Cells 28, 955–964.

Briley, D., Ginardi, V., Wolfer, R., Renck, A., Zolochevska, A., Taglialatela, G., Koch, P., Edenhofer, F., Hampi, A., and Brustle, O. (2010). Inhibition of notch signaling in human embryonic stem cell-derived neural stem cells delays G1/S phase transition and accelerates neuronal differentiation in vitro and in vivo. Stem Cells 28, 955–964.

Briley, D., Ginardi, V., Wolfer, R., Renck, A., Zolochevska, A., Taglialatela, G., Koch, P., Edenhofer, F., Hampi, A., and Brustle, O. (2010). Inhibition of notch signaling in human embryonic stem cell-derived neural stem cells delays G1/S phase transition and accelerates neuronal differentiation in vitro and in vivo. Stem Cells 28, 955–964.

Briley, D., Ginardi, V., Wolfer, R., Renck, A., Zolochevska, A., Taglialatela, G., Koch, P., Edenhofer, F., Hampi, A., and Brustle, O. (2010). Inhibition of notch signaling in human embryonic stem cell-derived neural stem cells delays G1/S phase transition and accelerates neuronal differentiation in vitro and in vivo. Stem Cells 28, 955–964.

Briley, D., Ginardi, V., Wolfer, R., Renck, A., Zolochevska, A., Taglialatela, G., Koch, P., Edenhofer, F., Hampi, A., and Brustle, O. (2010). Inhibition of notch signaling in human embryonic stem cell-derived neural stem cells delays G1/S phase transition and accelerates neuronal differentiation in vitro and in vivo. Stem Cells 28, 955–964.
Marathe, S., Jaquet, M., Annor, J.-M., and Alberi, L. (2017). Jagged1 is Altered in Alzheimer’s Disease and Regulates Spatial Memory Processing. Front. Cell. Neurosci. 11, 220.

Meyer, K., Feldman, H.M., Lu, T., Drake, D., Lim, E.T., Ling, K.-H., Bishop, N.A., Pan, Y., See, J., Lin, Y.-T., et al. (2019). REST and Neural Gene Network Dysregulation in iPSC Models of Alzheimer’s Disease. Cell Rep. 26, 1112–1127.e9.

Miller, J.A., Ding, S.L., Sunkin, S.M., Smith, K.A., Ng, L., Szafer, A., Ebbert, A., Riley, Z.L., Royall, J.J., Aiona, K., et al. (2014). Transcriptional landscape of the prenatal human brain. Nature 508, 199–206.

Moreno-Jiménez, E.P., Flor-Garcia, M., Terreros-Roncal, J., Rabano, A., Cappelen, M., Varela-Nallar, L., Aranguiz, F.C., Slater, P.G., and Inestrosa, N.C. (2010). Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in patients with Alzheimer’s disease. Nat. Med. 25, 554–560.

Oh, S.Y., Eilenstein, A., Chen, C.-D., Hirman, J.D., Berg, E.A., Costello, C.E., Yamir, R., Neve, R.L., and Abraham, C.R. (2005). Amyloid precursor protein interacts with notch receptors. J. Neurosci. Res. 82, 32–42.

Paredes, M.F., Sorrells, S.F., Cebrian-Silla, A., Sandoval, K., Qi, D., Kelley, K.W., James, D., Mayer, S., Chang, J., Auguste, K.I., et al. (2018). Does Adult Neurogenesis Persist in the Human Hippocampus? Cell Stem Cell 23, 780–781.

Quiroz, Y.T., Schultz, A.P., Chen, K., Protas, H.D., Brickhouse, M., Fleisher, A.S., Langbaum, J.B., Thiyyagarwa, P., Fagan, A.M., Shah, A.R., et al. (2015). Brain imaging and blood biomarker abnormalities in children with autosomal dominant Alzheimer disease: a cross-sectional study. JAMA Neurol. 72, 912–919.

Renner, M., Lancaster, M.A., Bian, S., Choi, H., Ku, T., Peer, A., Chung, K., and Knoblich, J.A. (2017). Self-organized developmental patterning and differentiation in cerebral organoids. EMBO J. 36, 1316–1329.

Ryan, N.S., Nicholas, J.M., Weston, P.S.J., Liang, Y., Mann, J.J., and Boldrini, M. (2018). Considerations for Assessing the Extent of Hippocampal Neurogenesis in the Adult and Aging Human Brain. Cell Stem Cell 23, 782–783.

Tensvall, T., Cheng, S.-K., Yuen, T.H., and二线, V. (2015). Cooperative roles of hydrophilic loop 1 and the C-terminus of presenilin 1 in the substrate-gating mechanism of γ-secretase. J. Neurosci. 35, 2646–2658.

Tartt, A.N., Fulmore, C.A., Liu, Y., Rosoklija, G.B., Dwork, A.J., Arango, V., Hen, R., Mann, J.J., and Bolardini, M. (2018). Early Changes in Hippocampal Neurogenesis in the Adult and Aging Human Brain. Cell Stem Cell 23, 974–982.e3.

Unger, M.S., Marschallinger, J., Kaindl, J., Höfling, C., Rossner, S., Heneka, M.T., Van der Linden, A., and Aigner, L. (2016). Adult hippocampal neurogenesis in aged adults and Alzheimer’s Disease Patients. Cell Stem Cell 24, 974–982.e3.

Varela-Nallar, L., Aranguiz, F.C., Slater, A.C., Laster, N.A., and Inestrosa, N.C. (2010). Immunohistological markers for staging neurodegeneration. Mol. Neurobiol. 43, 5796–5806.

Varela-Nallar, L., Aranguiz, F.C., Abbott, A.C., Slater, P.G., and Inestrosa, N.C. (2010). Adult hippocampal neurogenesis in aging and Alzheimer’s disease. Birth Defects Res. C Embryo Today 90, 284–298.

Von Bohlen Und Halbach, O. (2007). Immunohistochemical markers for staging neurodegeneration. Cell Tissue Res. 329, 409–420.

Wen, P.H., Shao, X., Shao, Z., Hof, P.R., Wisniewski, T., Kelley, K., Friedrich, V.L., Jr., Ho, L., Pasinetti, G.M., Shioi, J., et al. (2002). Overexpression of wild type but not an FAD mutant presenilin-1 promotes neurogenesis in the hippocampus of adult mice. Neurobiol. Dis. 10, 8–19.

Wen, P.H., Hof, P.R., Chen, X., Guic, K., Austin, G., Younkin, S.G., Younkin, L.H., DeGasperi, R., Garna Sosa, M.A., Robakis, N.K., et al. (2004). The presenilin-1 familial Alzheimer disease mutant P117L impairs neurogenesis in the hippocampus of adult mice. Exp. Neurol. 188, 224–237.

Woo, S.-M., Kim, J., Han, H.-W., Chae, J.-I., Son, M.-Y., Cho, S., Chang, H.-M., Han, Y.-M., and Kang, Y.-K. (2009). Notch signaling is required for maintaining stem-cell features of neuroprogenitor cells derived from human embryonic stem cells. BMC Neurosci. 10, 97.

Yang, C.-P., Gilley, J.A., Zhang, G., and Kernie, S.G. (2011). ApoE is required for maintenance of the dentate gyrus neural progenitor pool. Development 138, 4351–4362.

Yang, J., Zhao, H., Ma, Y., Shi, G., Song, J., Tang, Y., Li, S., Li, T., Liu, N., Tang, F., et al. (2017). Early pathogenic event of Alzheimer’s disease documented in iPS cells from patients with PSEN1 mutations. Oncotarget 8, 7900–7913.
## STAR METHODS

### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| b-III-tubulin       | Biolegend | Cat#801201; RRID: AB_2313773 |
| b-III-tubulin       | Biolegend | Cat#802001; RRID: AB_2564645 |
| K67                 | BD Bioscience | Cat#550609; RRID: AB_393778 |
| APP C-terminal fragment | Biolegend | Cat#802803; RRID: AB_2715853 |
| Aβ (6E10)           | Biolegend | Cat#803014; RRID: AB_2728527 |
| PSEN1               | Millipore | Cat#MAB232; RRID: AB_95175 |
| Notch ICD (Val 1744) | Cell Signaling Technologies | Cat#4147; RRID: AB_2153348 |
| β Actin             | Sigma | Cat#1978; RRID: AB_476692 |
| FOXG1               | Abcam | Cat#ab18259; RRID: AB_732415 |
| NESTIN              | Santa Cruz | Cat#sc-23927; RRID: AB_627994 |
| PAX6                | Biolegend | Cat#901301; RRID:AB_2565003 |
| **Chemicals, Peptides, and Recombinant Proteins** |        |            |
| Dispase             | ThermoFisher | 17105-041 |
| Accutase            | ThermoFisher | A11105-01 |
| SB431542            | R&D Systems | 1614/10 |
| Dorsomorphin        | R&D Systems | 3093/10 |
| N2 Supplement       | ThermoFisher | 17502-048 |
| B27 Supplement      | ThermoFisher | 17504-044 |
| POWER Sybr green    | ThermoFisher | 4368702 |
| Trizol              | ThermoFisher | 15596-026 |
| Essential 8 medium  | ThermoFisher | A1517001 |
| Laminin             | Sigma | L2020 |
| Matrigel            | Corning | 356255 |
| DAPT (γ-secretase inhibitor N-[N-(3, 5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester) | Tocris | 2634 |
| LY2886721           | Cambridge Bioscience | 2299-5 |
| Superscript IV      | ThermoFisher | 18091050 |
| Geltrex             | ThermoFisher | A1413302 |
| **Critical Commercial Assays** |        |            |
| Human (6E10) Aβ42 Ultra-Sensitive Kit | MesoScale Discovery | K151FUE |
| **Experimental Models: Cell Lines** |        |            |
| Ctrl 1 - Human iPSC | Dr Tilo Kunath; Arber et al., 2020 | N/A |
| Ctrl 2 - Human iPSC | Coriel cell repository | ND41886 |
| Ctrl 3 - Human iPSC | Sigma | RBK001-a |
| Ctrl 4 - Human iPSC | Sigma | SIGI1001-a-1 |
| Shef6 - Human ESC   | UK Stem Cell Bank | N/A |
| APP V717I patient 1 (2 clones) - Human iPSC | Stembancc | N/A |
| APP V717I patient 2 - Human iPSC | Arber et al., 2020 | N/A |
| PSEN1 int4del (2 clones) - Human iPSC | Stembancc | N/A |
| PSEN1 Y115H - Human iPSC | Arber et al., 2020 | N/A |
| PSEN1 M139V - Human iPSC | Stembancc | N/A |

(Continued on next page)
RESOURCE AVAILABILITY

Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Charlie Arber (c.arber@ucl.ac.uk).

Materials Availability
This study did not generate new unique reagents.

Data and Code Availability
This study did not generate any unique datasets or code. Published datasets analyzed in this study are GEO: GSE95315 (Hochgerner et al., 2018), and http://brainspan.org/ (Miller et al., 2014). Sequencing analysis code can be found at (https://github.com/harrislachlan/data).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Details of stem cell lines employed

| Cell line | No. of clones | Name and origin | Sex | Age at onset | Age at biopsy | APOE status |
|-----------|---------------|-----------------|-----|--------------|---------------|-------------|
| Ctrl1     |               | Dr Tilo Kunath  | M   | 78           |               | 3/3         |
| Ctrl2     |               | ND41886 Coriel  | M   | 64           |               | 2/3         |
| Ctrl3     |               | RBi001-a Sigma | M   | 45-49        |               | 3/3         |
| Ctrl4     |               | SGI1001-a-1 Sigma | F | 20-24        |               | 3/4         |
| Shef6 (hESC) | 1            | UK Stem Cell Bank | F | n/a          |               | 3/3         |
| APP V717I | 2             | StemBancc       | M   | 49           | 58            | 4/4         |
| APP V717I-2 | 1            | Arber et al., 2020 | F | Asymptomatic | 47            | 3/3         |
| PSEN1 int4del | 2           | Stembancc       | F   | 47           | 47            | 3/3         |
| PSEN1 Y115H | 1            | Arber et al., 2020 | M | 34           | 39            | 3/3         |
| PSEN1 M139V | 1            | Stembancc       | F   | 34           | 45            | 2/3         |
| PSEN1 M146I | 1            | Stembancc       | M   | Asymptomatic | 38            | 3/3         |
| PSEN1 R278I | 2            | Arber et al., 2020 | M | 58           | 60            | 2/4         |
Case information for post-mortem brain tissue

Fresh frozen post-mortem hippocampal tissue was made available through the Queen Square Brain Bank for Neurological Disorders. Tissue from five controls and seven fAD cases were available. Experimental group allocation was made via gene mutation status.

| PM delay | AAO | AAD | Duration | Gender | Clinical Diag | Path Diag | Brain Weight | Mutations | APOE | Braak | Thal | Phase | CERAD | ABC | CAA |
|----------|-----|-----|----------|--------|---------------|-----------|--------------|------------|------|-------|------|-------|-------|-----|-----|
| Control  | 16:15:00 | na | 88 | na | M | Control Path Aging | 1077 | Control 1 | 33 | 2 | 2 | B1 | 0 |
| Control  | 76:10:00 | na | 71 | na | F | Control Path Aging | 1214 | Control 2 | 33 | 3 | 2 | 0 | 1 |
| Control  | 47:05:00 | na | 89 | na | M | Control Control | 1356 | Control 3 | 33 | 2 | 3 | 1 | 2 |
| Control  | 59:57:00 | na | 96 | na | F | Control Control | 1032 | Control 4 | 33 | 2 | 2 | 0 | 1 |
| Control  | 38:00:00 | na | 96 | na | F | Control Control | 1092 | Control 5 | 2 | 1 | 0 | 1 |
| fAD      | 32:10:00 | 49 | 62 | 13 | M | fAD fAD | 1302 | APP V717L | 44 | 6 | 5 | 3 | 3 |
| fAD      | 68:05:00 | 60 | 66 | 6 | M | AD fAD | 1437 | APP V717 | 33 | 6 | 5 | 3 | 3 |
| fAD      | 43:10:00 | 42 | 51 | 9 | M | fAD fAD | 1415 | PSEN1 int4del | 33 | 6 | 5 | 3 | 3 |
| fAD      | 128:35:00 | 41 | 49 | 8 | F | fAD fAD | 1205 | PSEN1 M139V | 33 | 6 | 5 | 3 | 3 |
| fAD      | 77:45:00 | 51 | 66 | 15 | M | fAD fAD | 1106 | PSEN1 R278I | 23 | 6 | 5 | 3 | 3 |
| fAD      | 11:00:00 | 42 | 53 | 11 | F | fAD fAD | 994 | PSEN1 E280G | 34 | 6 | 5 | 3 | 3 |
| fAD      | 43:50:00 | 42 | 47 | 5 | M | MSA fAD | 1225 | PSEN1 A434T & T291A | 33 | 5 | 5 | 3 | 3 |

Abbreviations; fAD – familial Alzheimer’s disease, PM delay -post mortem delay, AAO – age at onset, AAD – age at death, CAA – cerebral amyloid angiopathy score

METHOD DETAILS

Cell culture

The iPSC lines employed in the study have been described previously (see STAR Methods; Arber et al., 2019, 2020). Where possible, data was corroborated with two iPSC clones from an individual donor, however, focus was made on increasing the number of individual donors to mitigate genetic variation and reduce false results (Germain and Testa, 2017). iPSCs were maintained in Essential 8 media on geltrex substrate and mechanically passaged using 0.5mM EDTA (all reagents ThermoFisher unless stated). Differentiation was employed following published protocols (Shi et al., 2012). Briefly, neural commitment was initiated with 10 μM SB431542 and 1 μM dorsomorphin (both R&D). Further patterning was performed in N2B27 media with retinoic acid. Cells were plated at day 18 on laminin (Sigma) coated 96 well plates and imaged at day 27.

Cerebral organoids were generated following published protocols (Lancaster et al., 2013). 9,000 iPSCs were seeded into embryoid bodies (EBs). EBs were embedded into Matrigel (Corning) on day 8 and maintained until day 45 at which point they were fixed in 4% para-formaldehyde for 2 hours, flushed with 30% sucrose solution and embedded in OCT cryo-embedding matrix. 10 μm sections were taken on a cryostat (Leica CM 1520).

Treatments were as follows; DAPT (N-[N-(3, 5-Difluorophenacetyl)-L-Alanyl]-S-phenylglycine t-butyl ester, Tocris) at 10 μM and LY2886721 (Cambridge Bioscience) at 1 μM, both for 5 days. Fold changes were measured relative to DMSO vehicle controls within each treatment plate.

Aβ42 ELISAs

48 hour conditioned media was collected and centrifuged at 2,000 g to remove cell debris. The human (6E10) Aβ42 ultra-sensitive electrochemiluminescent kit (Meso Scale Discovery) was used as per the manufacturers instructions.
**Immunocytochemistry**

Cells were fixed in 4% paraformaldehyde for 15 minutes, and subsequently permeabilised with 3 washes of PBST supplemented with 0.3% Triton X-100 (PBST). Blocking was then performed with 3% bovine serum albumin (Sigma) in PBST for 20 minutes at room temperature. Primary antibodies (listed in the Key Resources Table) were incubated in blocking solution overnight followed by three washes in PBST. Secondary antibodies (Alexafluor, Thermo) were incubated for 1 hour in the dark in blocking solution. DAPI nuclear counterstain was added in one of the final three PBS washes. Immunocytochemistry was performed in the same way on organoid sections.

Organoid relative progenitor-neural contribution was quantified at day 45. At least two neurogenic regions per organoid were selected based on morphology and FOXG1/PAX6/TUJ1 immunocytochemistry (for example, see Figure 1B). Within neurogenic regions, measurements were performed from basal membrane to neural boundaries in μm as depicted in Figure 4A. Measurements from basal membranes ensured full transverse sections of the neurogenic niche. Image capture and quantification was done in a genotype blinded manner.

High content imaging was performed on the Perkin Elmer Opera Phenix. At least 1000 cells were imaged per well in duplicate per time point and analysis was performed on the Columbus software. Images of organoid sections were taken on a Zeiss LSM microscope and analyzed using Leica LAS software. No post hoc manipulation was performed. Neurogenic scoring was performed blinded on the Leica LAS software.

**Immunohistochemistry**

10 μm sections of fresh frozen hippocampus were taken on the cryostat (Leica CM 1520) and stored at −80 degrees. Sections were fixed in 4% paraformaldehyde for 15 minutes. Staining was performed as above, however, secondary biotinylated antibodies and ABC signal amplification were used following primary antibody incubation. Signal was developed using DAB staining and counterstained with Meyer’s solution before dehydration, scoring and imaging. Quantification was made for each marker per 200 μm planar length of dentate gyrus. Scoring was performed in a genotype-blinded manner by three independent scorers. All case information is listed in STAR Methods.

**qPCR**

RNA was isolated using Trizol solution as per the manufacturers protocol. 2 μg of total RNA was reverse transcribed using SuperScript IV reverse transcriptase with random hexamer primers. qPCR was performed on an Agilent MX3000P with Power Sybr Green master mix (primer sequences in Key Resources Table). Analysis was performed using the ΔΔCT method.

**Western blotting**

Cells were lysed in RIPA buffer and 15–25 μg of total protein, determined using BCA assay (Biorad), was loaded onto precast gels Bis-Tris polyacrylamide gels (NuPage). After running in MES buffer, proteins were transferred onto a nitrocellulose membrane and blocked in 3% bovine serum albumin. Primary antibodies were incubated overnight in blocking solution. After incubation with secondary antibodies (Rockland), imaging and analysis were performed on the Li-Cor Odyssey Fc.

**BrainSpan data**

Expression data from human fetal tissue aged 15 – 21 weeks post conception was leveraged from http://brainspan.org/ (Miller et al., 2014). Z scores were calculated across the developmental cortical layers and data was presented as a heatmap in Figure 1.

**Analysis of single cell RNA-seq data**

The mapped single-cell RNA sequencing dataset A (GSE95315) from the originating study (Hochgerner et al., 2018) were read into Seurat (Ver. 3.1.2) for analysis (Stuart et al., 2019). The dataset A contains the transcriptomes of 5, 454 cells from mouse dentate gyri ranging from P12-P35. The adult hippocampal NSCs (AH-NSCs), intermediate neuronal progenitor cells (IPCs) and granule neuron clusters were identified according to marker gene expression. Briefly, the cluster of AH-NSCs was identified based on a Apoe-high/Hopx-high/Aqp4-low expression profile (Harris et al., 2020), whereas IPCs had high expression of Eomes and of a variety of cell-cycle marker genes (e.g Mcm2-7, Mki67). Finally, the granule neuron cluster was identified based on high expression of Tubb3, Prox1 and the absence of the aforementioned markers. Differential gene expression testing between AH-NSCs and granule neurons was performed using the FindMarkers function in Seurat. This function determines differential expression by comparing gene expression levels across all cells in a particular cluster (not just positive cells). The tests were performed on the normalized data located in the “data” slot of the “RNA” assay (Hafemeister and Satija, 2019). Genes were tested for differential gene expression if they were expressed by at least 10% of cells in at least one of the cellular clusters being compared. No minimum log-fold change threshold was enforced. Statistical significance (p < 0.05) was determined using Wilcoxon rank sum tests and the P-value was corrected for multiple-testing using the False Discovery Rate. All analysis was performed in R (3.6.2).
QUANTIFICATION AND STATISTICAL ANALYSIS

Statistics
Data were collated in Microsoft Excel and GraphPad Prism 7. Normality was tested via D’Agostino-Pearson, or Shapiro-Wilk tests in the case of fewer repeats. Pooled controls and pooled mutation lines were compared via ANOVA with post hoc Tukey as indicated in the figure legends. See Table S1 for all tests used, exact P values, confidence intervals and degrees of freedom. P values are represented by * p < 0.05, ** p < 0.01, *** p < 0.001. Multiple independent neural inductions were performed for each iPSC line and exact numbers are shown within histograms.
Supplemental Information

Familial Alzheimer's Disease Mutations in PSEN1
Lead to Premature Human Stem Cell Neurogenesis

Charles Arber, Christopher Lovejoy, Lachlan Harris, Nanet Willumsen, Argyro Alatza, Jackie M. Casey, Georgie Lines, Caomhe Kerins, Anika K. Mueller, Henrik Zetterberg, John Hardy, Natalie S. Ryan, Nick C. Fox, Tammaryn Lashley, and Selina Wray
Fig S1 – Intensity analysis of images in Fig 1B.
A-B) APP immunostaining (C terminal fragment and 6E10 recognising Aβ) shows increased intensity in the neural regions (marked by TUJ1). C) PSEN1 immunostaining shows a more homogeneous expression across pro-neural and neural regions. D) Notch intracellular domain (Notch ICD) is enriched in neural progenitor regions. A-D are adjacent sections.
Figure S2 – Aβ42 ELISA and images of all iPSC lines at 27 DIV.
A) ELISA measurement of Aβ42 release from neuronal cultures to confirm the action of β- and γ-secretase inhibitors (see Fig 2). B) Representative images of all lines at day 27 of induction, used for quantification of Ki67 proliferating progenitors and TUJ1 post-mitotic neurons (see Fig 3).
Figure S3 – Data from Fig 3 and Fig 4 regrouped via APOE genotype.
Symbols: Ctrl1 – blue circles. Ctrl2 – blue squares. Ctrl3 – blue triangles. Ctrl4 – blue diamonds. hESC – black crosses. APP V717I – purple circles. PSEN1 int4del – pink circles. PSEN1 Y115H – pink squares. PSEN1 M139V – green triangles. PSEN1 M146I – green diamonds. PSEN1 R278I – green hexagons.
Figure S4

A) Low magnification images for Fig 6. Boxes represent images from Fig 6 and dotted lines depict the granule layer of the dentate gyrus. Scale bar represents 200μm.

B) Analysis for TUJ1 neurite density and NESTIN staining in hippocampi grouped via genotype.

Figure S4 – Low magnification images of post mortem hippocampi and quantification grouped via genotype. A) Low magnification images for Fig 6. Boxes represent images from Fig 6 and dotted lines depict the granule layer of the dentate gyrus. Scale bar represents 200μm. B) Analysis for TUJ1 neurite density and NESTIN staining in hippocampi grouped via genotype.